
CLAIMS

What is claimed is:


~~1. A method of treating or managing cancer, comprising administering to a patient in need of such treatment or management a therapeutically effective amount of (i) Compound A~~



~~Compound A~~

~~or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and (ii) daratumumab.~~

~~2. A method of treating or managing cancer, comprising administering to a patient in need of such treatment or management a therapeutically effective amount of (i) Compound A~~



~~Compound A~~

~~or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, (ii) daratumumab and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.~~

~~3. The method of claim 1 or 2, wherein the cancer is multiple myeloma.~~

~~4. The method of claim 3, wherein the multiple myeloma is smoldering myeloma, indolent myeloma, active multiple myeloma, extramedullary plasmacytoma, solitary plasmacytoma of the bone, light chain myeloma, or non-secretory myeloma.~~

~~5. The method of claim 3, wherein the multiple myeloma is relapsed or refractory.~~

~~6. The method of claim 3, wherein the multiple myeloma is drug-resistant.~~

~~7. The method of claims 3, wherein the multiple myeloma is newly diagnosed.~~

~~8. A method for treating or managing multiple myeloma, comprising:~~

~~(i) identifying a patient having multiple myeloma sensitive to treatment with (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and (b) daratumumab; and~~

~~(ii) administering to the patient a therapeutically effective amount of (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and (b) daratumumab.~~

~~9. A method for treating or managing multiple myeloma, comprising:~~

~~(i) identifying a patient having multiple myeloma sensitive to treatment with (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof; and~~

(ii) administering to the patient a therapeutically effective amount of (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

10. The method of claim 8 or 9, wherein the multiple myeloma is relapsed or refractory.

11. The method of claim 8 or 9, wherein the multiple myeloma is drug-resistant.

12. The method of claim 8 or 9, wherein the multiple myeloma is newly diagnosed.

13. The method of any one of claims 1-12, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is administered in an amount of from about 0.5 to about 100 mg per day, and (ii) daratumumab is administered in an amount of from about 16 to about 200 mg/kg per day.

14. The method of any one of claims 1-12, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is administered in an amount of from about 0.5 to about 100 mg per day, (ii) daratumumab is administered in an amount of from about 16 to about 200 mg/kg per day and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is administered in an amount of from about 20 to about 200 mg.

15. The method of claim 13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is administered in an amount of from about 0.5 to about 5 mg per day, and (ii) daratumumab is administered in an amount of from about 16 to about 25 mg/kg per day.

16. The method of claim 13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate,

~~or polymorph thereof, is administered in an amount of about 0.5, 1, 2, 2.5, 3, 4, 5, 7.5, 10, 15, 20, 25, 50 or 100 mg per day, and (ii) daratumumab is administered in an amount of about 16, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150 or 200 mg/kg per day.~~

~~17. The method of claim 13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is administered orally and (ii) daratumumab is administered intravenously.~~

~~18. The method of claim 13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is administered in a capsule or tablet and (ii) daratumumab is administered by injection or infusion.~~

~~19. The method of claim 18, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is administered in 10 mg or 25 mg of a capsule and (ii) daratumumab is administered as intravenous infusion of diluted 20 mg/ml single dose vial.~~

~~20. The method of claim 14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is administered in an amount of from about 0.5 to about 5 mg per day, (ii) daratumumab is administered in an amount of from about 16 to about 25 mg/kg per day and (iii) dexamethasone is administered in an amount of from about 20 to about 50 mg per day.~~

~~21. The method of claim 14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is administered in an amount of about 0.5, 1, 2, 2.5, 3, 4, 5, 7.5, 10, 15, 20, 25, 50 or 100 mg per day, (ii) daratumumab is administered in an amount of about 16, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150 or 200 mg/kg per day and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is administered in an amount of about 20, 25, 30, 35, 40, 45, 50, 75, 100, 150 or 200 mg per day.~~

~~22. The method of claim 14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is administered orally, (ii) daratumumab is administered intravenously and (iii) dexamethasone is administered orally or by injection.~~


~~23. The method of claim 14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is administered in a capsule or tablet, (ii) daratumumab is administered by injection or infusion and (iii) dexamethasone is administered in a tablet.~~

~~24. The method of claim 23, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is administered in 10 mg or 25 mg of a capsule, (ii) daratumumab is administered as intravenous infusion of diluted 20 mg/ml single dose vial and (iii) dexamethasone is administered as 0.5 mg or 0.75 mg of a tablet .~~

~~25. The method of any one of claims 1-24, wherein the multiple myeloma is relapsed, refractory or resistant to conventional therapy.~~

~~26. The method of any one of claims 1-25, wherein the compounds are administered in a 28 day cycle.~~


~~27. The method of any one of claim 1-26, wherein the compound is Compound A-S~~



~~Compound A-S~~

~~or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.~~


~~28~~1. Use of ~~A~~a compound in the manufacture of a medicament for ~~use in a method of~~ treating or managing cancer, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof ~~for use in a method of treating or managing cancer~~, wherein ~~the method comprises administering to a patient in need of such treatment or management~~ a therapeutically effective amount of (i) Compound A or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, and (ii) daratumumab is to be administered to a patient in need of such treatment or management.

~~29~~2. Use of ~~A~~a compound in the manufacture of a medicament for ~~for use in a method of~~ treating or managing cancer, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof ~~for use in a method of treating or managing cancer~~, wherein ~~the method comprises administering to a patient in need of such treatment or management~~ a therapeutically effective amount of (i) Compound A or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, (ii) daratumumab and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered to a patient in need of such treatment or management.

~~30~~3. The ~~compound for use~~ use according to claim ~~28~~1 or ~~29~~2, wherein the cancer is multiple myeloma.

~~31~~4. The ~~compound for use~~ use according to claim ~~30~~3, wherein the multiple myeloma is smoldering myeloma, indolent myeloma, active multiple myeloma, extramedullary plasmacytoma, solitary plasmacytoma of the bone, light chain myeloma, or non-secretory myeloma.

~~32~~5. The ~~compound for use~~ use according to claim ~~30~~3, wherein the multiple myeloma is relapsed or refractory.

~~33~~6. The ~~compound for~~ use according to claim ~~30~~3, wherein the multiple myeloma is drug-resistant.

~~34~~7. The ~~compound for~~ use according to ~~30~~3, wherein the multiple myeloma is newly diagnosed.

~~35~~8. Use of a ~~A~~ compound in the manufacture of a medicament for ~~for use in a method of~~ treating or managing multiple myeloma, wherein the compound is Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof,~~ wherein the method comprises~~wherein :
~~(i) identifying a patient having multiple myeloma sensitive to treatment with (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and (b) daratumumab; and~~
~~(ii) administering to the patient~~ a therapeutically effective amount of (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and (b) daratumumab is to be administered to a patient, wherein the patient is identified as having multiple myeloma sensitive to treatment with (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal clathrate or polymorph thereof and (b) daratumumab.

~~36~~9. Use of a ~~A~~ compound in the manufacture of a medicament for ~~for use in a method of~~ treating or managing multiple myeloma, wherein the compound is Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein ~~the method comprises:~~

~~(i) identifying a patient having multiple myeloma sensitive to treatment with (a Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof; and~~

~~(ii) administering to the patient~~ a therapeutically effective amount of (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered to a patient, wherein the patient is identified as having multiple myeloma sensitive to treatment with (a) Compound A, or

an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

~~37~~10. The ~~compound for~~ use according to claim ~~35~~8 or ~~36~~9, wherein the multiple myeloma is relapsed or refractory.

~~38~~11. The ~~compound for~~ use according to claim ~~35~~8 or ~~36~~9, wherein the multiple myeloma is drug-resistant.

~~39~~12. The ~~compound for~~ use according to claim ~~35~~8 or ~~36~~9, wherein the multiple myeloma is newly diagnosed.

~~40~~13. The ~~compound for~~ use according to any one of claims ~~28~~2-~~39~~12, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of from about 0.5 to about 100 mg per day, and (ii) daratumumab is administered in an amount of from about 16 to about 200 mg/kg per day.

~~41~~14. The ~~compound for~~ use according to any one of claims ~~28~~2-~~39~~12, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, ~~sis~~ is to be administered in an amount of from about 0.5 to about 100 mg per day, (ii) daratumumab is administered in an amount of from about 16 to about 200 mg/kg per day and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of from about 20 to about 200 mg.

~~42~~15. The ~~compound for~~ use according to claim ~~40~~13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, ~~sis~~is to be administered in an amount of from about 0.5 to about 5 mg per day, and (ii) daratumumab is to be administered in an amount of from about 16 to about 25 mg/kg per day.

~~43~~16. The ~~compound for~~ use according to claim ~~40~~13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of about 0.5, 1, 2, 2.5, 3, 4, 5, 7.5, 10, 15, 20, 25, 50 or 100 mg per day, and (ii) daratumumab is to be administered in an amount of about 16, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150 or 200 mg/kg per day.

~~44~~17. The ~~compound for~~ use according to claim ~~40~~13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof ~~sis~~ is to be administered orally and (ii) daratumumab is to be administered intravenously.

~~45~~18. The ~~compound for~~ use according to claim ~~40~~13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered in a capsule or tablet and (ii) daratumumab is to be administered by injection or infusion.

~~46~~19. The ~~compound for~~ use according to claim ~~45~~18, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered in 10 mg or 25 mg of a capsule and (ii) daratumumab is to be administered as intravenous infusion of diluted 20 mg/ml single dose vial.

~~47~~20. The ~~compound for~~ use according to claim ~~41~~14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of from about 0.5 to about 5 mg per day, (ii) daratumumab is to be administered in an amount of from about 16 to about 25 mg/kg per day and (iii) dexamethasone is to be administered in an amount of from about 20 to about 50 mg per day.

~~48~~21. The ~~compound for~~ use according to claim ~~41~~14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of about

0.5, 1, 2, 2.5, 3, 4, 5, 7.5, 10, 15, 20, 25, 50 or 100 mg per day, (ii) daratumumab is to be administered in an amount of about 16, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150 or 200 mg/kg per day and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of about 20, 25, 30, 35, 40, 45, 50, 75, 100, 150 or 200 mg per day.

~~49~~22. The ~~compound for~~ use according to claim ~~41~~14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered orally, (ii) daratumumab is to be administered intravenously and (iii) dexamethasone is to be administered orally or by injection.


~~50~~23. The ~~compound for~~ use according to claim ~~41~~14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered in a capsule or tablet, (ii) daratumumab is to be administered by injection or infusion and (iii) dexamethasone is to be administered in a tablet.

~~51~~24. The ~~compound for~~ use according to claim ~~50~~23, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered in 10 mg or 25 mg of a capsule, (ii) daratumumab is to be administered as intravenous infusion of diluted 20 mg/ml single dose vial and (iii) dexamethasone is to be administered as 0.5 mg or 0.75 mg of a tablet .

~~52~~25. The ~~compound for~~ use according to claim any one of claims ~~28~~2-~~51~~24, wherein the multiple myeloma is relapsed, refractory or resistant to conventional therapy.

~~53~~26. The ~~compound for~~ use according to claim any one of claims ~~28~~2-~~52~~25, wherein the compounds are to be administered in a 28 day cycle.

~~54.~~27. The ~~compound for~~ use according to claim any one of claims ~~28~~2-~~53~~26, wherein the compound is Compound A-S



Compound A-S

or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.